Response to Editor: Commentary on "Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma"

被引：0
|
作者：
Chen, Qin [1 ,2 ,3 ]
Wang, Xinyue [1 ,2 ]
Jiang, Richeng [1 ,2 ,4 ,5 ]
机构：
[1] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Tianjin Lung Canc Ctr, Dept Thorac Oncol, Tianjin, Peoples R China
[2] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[3] Tianjin Chest Hosp, Dept Resp & Crit Med, Tianjin, Peoples R China
[4] Tianjin Canc Hosp, Airport Hosp, Canc Precise Diag Ctr, Tianjin, Peoples R China
[5] Tianjin Med Univ Canc Inst & Hosp, Ctr Precis Canc Med & Translat Res, Tianjin, Peoples R China
来源：
CLINICAL LUNG CANCER | 2024年 / 25卷 / 08期
基金：
中国国家自然科学基金;
关键词：
THERAPY; MECHANISM;
D O I：
10.1016/j.clc.2024.08.013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：e479 / e481
页数：3
相关论文
共 50 条
  • [41] Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
    Dantoing, Edouard
    Piton, Nicolas
    Salaun, Mathieu
    Thiberville, Luc
    Guisier, Florian
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)
  • [42] Optimal Selection of Patients with Genitourinary Cancers for Anti-PD1/PD-L1 Treatment with a Focus on Urothelial and Renal Cell Carcinoma
    Zeuschner, Philip
    Junker, Kerstin
    EUROPEAN UROLOGY FOCUS, 2022, 8 (04): : 907 - 909
  • [43] The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma
    Matsubara, Yuki
    Toriyama, Kazuhiro
    Kadowaki, Shigenori
    Ogata, Takatsugu
    Nakazawa, Taiko
    Kato, Kyoko
    Nozawa, Kazuki
    Narita, Yukiya
    Honda, Kazunori
    Masuishi, Toshiki
    Bando, Hideaki
    Ando, Masashi
    Tajika, Masahiro
    Oze, Isao
    Hosoda, Waki
    Muro, Kei
    ESOPHAGUS, 2023, 20 (03) : 524 - 532
  • [44] The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma
    Yuki Matsubara
    Kazuhiro Toriyama
    Shigenori Kadowaki
    Takatsugu Ogata
    Taiko Nakazawa
    Kyoko Kato
    Kazuki Nozawa
    Yukiya Narita
    Kazunori Honda
    Toshiki Masuishi
    Hideaki Bando
    Masashi Ando
    Masahiro Tajika
    Isao Oze
    Waki Hosoda
    Kei Muro
    Esophagus, 2023, 20 : 524 - 532
  • [45] Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
    Janning, Melanie
    Kobus, Franca
    Babayan, Anna
    Wikman, Harriet
    Velthaus, Janna-Lisa
    Bergmann, Sonja
    Schatz, Stefanie
    Falk, Markus
    Berger, Lars-Arne
    Boettcher, Lisa-Marie
    Paesler, Sarina
    Gorges, Tobias M.
    O'Flaherty, Linda
    Hille, Claudia
    Joosse, Simon A.
    Simon, Ronald
    Tiemann, Markus
    Bokemeyer, Carsten
    Reck, Martin
    Riethdorf, Sabine
    Pantel, Klaus
    Loges, Sonja
    CANCERS, 2019, 11 (06):
  • [46] Efficacy and Genomic Correlates of Response to Anti-PD1/PD-L1 Blockade in Non-Small Cell Lung Cancers Harboring Targetable Oncogenes
    Vokes, N.
    Jimenez Alguilar, E.
    Adeni, A.
    Umeton, R.
    Sholl, L.
    Rizvi, H.
    Hellmann, M.
    Awad, M.
    Van Allen, E.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S422 - S422
  • [47] INCREASED PD-L1 TUMOR EXPRESSION CORRELATES WITH HIGH RATE OF RESPONSE TO PD-1 INHIBITORS IN PATIENTS WITH UNRESECTABLE, RECURRENT, AND METASTATIC CUTANEOUS SQUAMOUS CELL CARCINOMA
    Bowers, Nate
    Burcher, Kimberly
    Savas, Jess
    Williford, Phillip
    Doerfler, Laura
    Patwa, Hafiz Shabbir
    Waltonen, Joshua
    Sullivan, Christopher
    Brown, James
    Porosnicu, Mercedes
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A132 - A133
  • [48] Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma
    Hsieh, Chih-Cheng
    Hsu, Han-Shui
    Li, Anna Fen-Yau
    Chen, Yann-Jang
    JOURNAL OF THORACIC DISEASE, 2018, 10 (07) : 4433 - 4444
  • [49] Predictive Factors of Response to PD-(L)1 Inhibitors in Patients With Advanced Non-Small Cell Lung and High PD-L1 Expression
    Barba Joaquin, A.
    Mosquera, J.
    Riudavets Melia, M.
    Gomez-Randulfe, M. I.
    Garcia Campelo, M. R.
    Sullivan, I.
    Serra Lopez, J.
    Aguado, M.
    Piedra, A.
    Majem, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1081 - S1081
  • [50] Mild hyperthermia upregulates PD-L1 in the tumor microenvironment and enhances antitumor efficacy of PD-L1 blockade in murine squamous cell carcinoma
    Ohta, Yuya
    Ichimura, Norihisa
    Yamaguchi, Satoshi
    Ohara, Go
    Yamamoto, Noriyuki
    Itoh, Yoshiyuki
    Yamada, Keiichiro
    Nakamura, Seiji
    Hibi, Hideharu
    NAGOYA JOURNAL OF MEDICAL SCIENCE, 2024, 86 (03): : 497 - 506
12345